These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8648250)

  • 41. Overexpression of protein kinase A - RIalpha reduces lipofection efficiency of cisplatin-resistant human tumor cells.
    Son KK; Rosenblatt J
    Cancer Lett; 2001 Apr; 165(1):81-6. PubMed ID: 11248422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation.
    Gorodetsky R; Levy-Agababa F; Mou X; Vexler AM
    Int J Cancer; 1998 Feb; 75(4):635-42. PubMed ID: 9466668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line.
    Geldof AA; Kruit A; Newling DW; Slotman BJ
    Anticancer Res; 1999; 19(1A):505-8. PubMed ID: 10226589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological effects of combined ultrasound and cisplatin treatment on ovarian carcinoma cells.
    Bernard V; Skorpíková J; Mornstein V; Slaninová I
    Ultrasonics; 2010 Mar; 50(3):357-62. PubMed ID: 19740505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo.
    Eichholtz-Wirth H; Hietel B
    Br J Cancer; 1994 Oct; 70(4):579-84. PubMed ID: 7522509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells.
    Britten RA; Peacock J; Warenius HM
    Radiother Oncol; 1992 Mar; 23(3):170-5. PubMed ID: 1574595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
    Chowanadisai W; Messerli SM; Miller DH; Medina JE; Hamilton JW; Messerli MA; Brodsky AS
    PLoS One; 2016; 11(3):e0151089. PubMed ID: 26986722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
    O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
    Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
    De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
    Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.
    Egawa-Takata T; Endo H; Fujita M; Ueda Y; Miyatake T; Okuyama H; Yoshino K; Kamiura S; Enomoto T; Kimura T; Inoue M
    Cancer Sci; 2010 Oct; 101(10):2171-8. PubMed ID: 20678156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines.
    Gorodetsky R; Mou X; Pfeffer MR; Peretz T; Levy-Agababa F; Vexler AM
    Isr J Med Sci; 1995; 31(2-3):95-100. PubMed ID: 7744601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
    Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tannic acid, an inhibitor of poly(ADP-ribose) glycohydrolase, sensitizes ovarian carcinoma cells to cisplatin.
    Sun Y; Zhang T; Wang B; Li H; Li P
    Anticancer Drugs; 2012 Oct; 23(9):979-90. PubMed ID: 22785358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
    Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ
    Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of 41 degrees C and 43 degrees C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin.
    Bergs JW; Haveman J; Ten Cate R; Medema JP; Franken NA; Van Bree C
    Oncol Rep; 2007 Jul; 18(1):219-26. PubMed ID: 17549371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
    Wang M; Ma X; Wang J; Wang L; Wang Y
    Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.